Aldeyra Therapeutics (id:5317 ALDX)
4.85 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 11:31:01 AM)
Exchange closed, opens in 1 day 21 hours
About Aldeyra Therapeutics
Market Capitalization 279.88M
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Headquarters (address) |
131 Hartwell Avenue Lexington 02421 MA United States |
| Phone | 781 761 4904 |
| Website | https://www.aldeyra.com |
| Employees | 10 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ALDX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.43 - 6.55 |
| Market Capitalization | 279.88M |
| P/E trailing | -7.58 |
| P/E forward | -7.70 |
| Price/Book | 3.29 |
| Beta | 1.43 |
| EPS | -0.750 |
| EPS United States (ID:6, base:3400) | 24.26 |